Article

Clinical Utility of Assessing CDKN2A Status in Recurrent Astrocytomas

2024-10-15

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> IDH-mutant astrocytomas exhibit a more indolent natural history and better prognosis compared to their IDH-wild type counterparts. The 2021 WHO classification integrated <italic>CDKN2A/B</italic>homozygous deletion as a crucial criterion for grading these tumors, emphasizing its prognostic implications. FISH assay is commonly used to assess <italic>CDKN2A</itali...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ebbf479b-a9de-534c-afd9-9e2ca091876c
DOI: 10.21203/rs.3.rs-4758261/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Clinical Utility of Assessing CDKN2A Status in Recurrent AstrocytomasDOI 10.21203/rs.3.rs-4758261/v1Read

CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.Semantic proximity Read

Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas.Semantic proximity Read

Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosisSemantic proximity Read

Role of CDKN2A deletion in grade 2/3 IDH-mutant astrocytomas: need for selective approach in resource-constrained settingsSemantic proximity Read

CDKN2A/B Homozygous Deletions in Astrocytomas: A Literature ReviewSemantic proximity Read

Expanding the molecular grading criteria in IDH-mutant astrocytoma.Semantic proximity Read

Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.Semantic proximity Read

Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.Semantic proximity Read

Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective study.Semantic proximity Read

Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma.Semantic proximity Read

Molecular and clinical prognostic factors in isocitrate dehydrogenase-mutant astrocytomas: Insights into biomarker-driven stratification.Semantic proximity Read

Molecular Characterization of IDH Wild-type Diffuse Astrocytomas: The Potential of cIMPACT-NOW Guidelines.Semantic proximity Read